National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW 2052, Australia.
Int J Drug Policy. 2010 Sep;21(5):347-58. doi: 10.1016/j.drugpo.2009.11.007. Epub 2010 Feb 1.
Amphetamine type stimulants (ATS) have become the focus of increasing attention worldwide. There are understandable concerns over potential harms including the transmission of HIV. However, there have been no previous global reviews of the extent to which these drugs are injected or levels of HIV among users. A comprehensive search of the international peer-reviewed and grey literature was undertaken. Multiple electronic databases were searched and documents and datasets were provided by UN agencies and key experts from around the world in response to requests for information on the epidemiology of use. Amphetamine or methamphetamine (meth/amphetamine, M/A) use was documented in 110 countries, and injection in 60 of those. Use may be more prevalent in East and South East Asia, North America, South Africa, New Zealand, Australia and a number of European countries. In countries where the crystalline form is available, evidence suggests users are more likely to smoke or inject the drug; in such countries, higher levels of dependence may be occurring. Equivocal evidence exists as to whether people who inject M/A are at differing risk of HIV infection than other drug injectors; few countries document HIV prevalence/incidence among M/A injectors. High risk sexual behaviour among M/A users may contribute to increased risk of HIV infection, but available evidence is not sufficient to determine if the association is causal. A range of possible responses to M/A use and harm are discussed, ranging from supply and precursor control, to demand and harm reduction. Evidence suggests that complex issues surround M/A, requiring novel and sophisticated approaches, which have not yet been met with sufficient investment of time or resources to address them. Significant levels of M/A in many countries require a response to reduce harms that in many cases remain poorly understood. More active models of engagement with M/A users and provision of services that meet their specific needs are required.
苯丙胺类兴奋剂(ATS)已成为全球关注的焦点。人们对潜在危害表示理解,包括 HIV 的传播。然而,此前尚无全球评估这些药物的注射程度或使用者中 HIV 水平的评估。我们对国际同行评议文献和灰色文献进行了全面检索。针对使用情况流行病学信息的请求,我们检索了多个电子数据库,并由联合国机构和世界各地的主要专家提供文件和数据集。在 110 个国家记录了安非他命或甲基苯丙胺(冰毒/安非他命,M/A)的使用情况,其中 60 个国家有注射使用情况。东亚和东南亚、北美、南非、新西兰、澳大利亚和一些欧洲国家的使用情况可能更为普遍。在可获得晶体形式的国家,有证据表明使用者更有可能吸食或注射该药物;在这些国家,可能出现更高水平的依赖性。关于注射 M/A 的人是否比其他药物注射者面临更大的 HIV 感染风险,存在不确定的证据;很少有国家记录 M/A 注射者的 HIV 流行率/发病率。M/A 用户的高危性行为可能导致 HIV 感染风险增加,但现有证据不足以确定这种关联是否具有因果关系。文中讨论了一系列可能针对 M/A 使用和危害的应对措施,从供应和前体控制,到需求和减少危害。有证据表明,M/A 问题复杂,需要新颖和复杂的方法,但尚未投入足够的时间和资源来解决这些问题。许多国家存在大量 M/A,需要采取措施减少危害,但在许多情况下,对这些危害的了解仍很有限。需要与 M/A 用户更积极地接触,并提供满足其特定需求的服务。